DexCom Target of Unusually High Options Trading (NASDAQ:DXCM)

DexCom, Inc. (NASDAQ:DXCM) was the recipient of some unusual options trading activity on Thursday. Stock traders acquired 21,773 call options on the company. This is an increase of 172% compared to the average daily volume of 8,014 call options.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. Argus assumed coverage on DexCom in a research note on Thursday, August 21st. They set a “buy” rating and a $100.00 price target for the company. Citigroup cut their target price on shares of DexCom from $105.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, October 7th. Stifel Nicolaus assumed coverage on shares of DexCom in a research report on Tuesday, October 21st. They set a “buy” rating and a $85.00 target price for the company. Piper Sandler set a $100.00 target price on shares of DexCom and gave the stock an “overweight” rating in a research report on Tuesday, October 21st. Finally, Robert W. Baird cut their price objective on shares of DexCom from $112.00 to $90.00 and set an “outperform” rating for the company in a report on Friday, September 26th. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, DexCom has a consensus rating of “Moderate Buy” and a consensus price target of $97.19.

DexCom Price Performance

DXCM stock opened at $68.20 on Friday. The firm has a 50 day moving average of $71.42 and a 200-day moving average of $77.96. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. DexCom has a 12 month low of $57.52 and a 12 month high of $93.25. The firm has a market capitalization of $26.74 billion, a P/E ratio of 47.36, a price-to-earnings-growth ratio of 1.43 and a beta of 1.47.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same period last year, the firm earned $0.45 EPS. The business’s quarterly revenue was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that DexCom will post 2.03 earnings per share for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, Director Kyle Malady sold 667 shares of the stock in a transaction on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the completion of the transaction, the director directly owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total value of $222,915.00. Following the transaction, the director directly owned 51,121 shares of the company’s stock, valued at approximately $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,383 shares of company stock valued at $434,274 over the last quarter. 0.32% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DexCom

Large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in shares of DexCom by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock valued at $4,218,063,000 after acquiring an additional 866,506 shares during the last quarter. Jennison Associates LLC lifted its position in DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after purchasing an additional 994,300 shares during the last quarter. Geode Capital Management LLC lifted its position in DexCom by 3.4% during the second quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in DexCom by 22.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock valued at $691,336,000 after purchasing an additional 1,868,241 shares during the last quarter. Finally, Nuveen LLC bought a new stake in DexCom during the first quarter valued at approximately $554,893,000. Institutional investors own 97.75% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.